

IIT-K, I2Cure to advance research on molecular iodine-based products

27 April 2021 | News

Under the terms of the agreement, I2Cure future products would be incubated at IIT-Kanpur

The Indian Institute of Technology-Kanpur (IIT-K) has collaborated with I₂Cure (P) Ltd, a 'Make in India for the world' biotech company for all future research on molecular iodine-based products that would be undertaken by the Biological Sciences & Bioengineering wing of IIT-K.

I₂Cure is the first biotechnology company in the world to produce molecular iodine-based i2cure BioShield', which is a broad-spectrum antimicrobial with proven efficacy of 99.999 per cent against SARS-CoV-2.

Under the terms of the agreement, I₂Cure future products would be incubated at IIT-Kanpur. The relationship would be of the equity partners, and validations of Dr Jack Kessler's global research would be done for Indian conditions at IIT-K.

IIT-K would also work with I₂Cure to develop new 'Made in India' products for global markets, especially in tackling long-term problems in the space of human preventive health, veterinary science (FMD, Bovine mastitis, dermatitis), and agri products.

Stating on this momentous occasion, Anil Kejriwal, Founder, Chairman, I₂Cure shared, "We would jointly be happy to contribute towards the vision of the Prime Minister of India to double agricultural income as well as become a \$5 trillion economy.

Adding to it, (Prof) Dr Ashok Kumar, Biological Sciences & Bioengineering at IIT Kanpur (BSBE), added, "We're excited about the prospects of IIT-K researched and curated solutions getting global attention."